ClinicalTrials.gg
CompletedNCT00861926Updated May 7, 2026Results posted

Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)

A Phase 3 interventional study of Salbutamol and Beclomethasone dipropionate + Formoterol in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 206 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,714
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
Largest of 40
1,714 · median 67
Started
2009
with 1 other
Phase 3
20 of 40
none open now
Registered
12th of 40
by date
Lead sponsor
12 of 40
Chiesi Farmaceutici S.p.A.

Among the 40 studies testing beclomethasone in Asthma, this one has the largest enrollment, is one of 2 that started in 2009, is one of 20 in phase 3, and was the 12th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

Primary objective:

The primary objective of the study was to compare the efficacy of Maintenance and Reliever Therapy (MART) with Foster® 100/6 μg (one inhalation bid) plus additional inhalations as needed, with the standard treatment of Foster® 100/6 μg (one inhalation bid) plus salbutamol 100 μg (Ventolin ®) additional inhalations as needed in not fully controlled asthmatic patients.

Secondary objectives:

The secondary objectives of the study were:

  • to evaluate the effect of treatments on lung function parameters and on other clinical outcome measures, and
  • to assess the safety and the tolerability of Foster® as MART.
Read the detailed description

This was a 48-week phase III, double-blind, randomized, 2-arm parallel group study in asthmatic patients (adults of both sexes) not fully controlled under ICS treatment.

The study plan included:

  • A pre-screening visit (V0, 3-10 days before V1) to explain the aim of the study, to sign the informed consent form and to prepare patients for V1;
  • A screening visit (V1, week -2) to assess inclusion/exclusion criteria followed by a 2-week run-in period when the patients received Foster® 100/6μg, one inhalation twice a day plus salbutamol for reliever medication;
  • A randomization visit (V2, week 0) when patients were allocated to one of the two treatment arms:

A) Foster® 100/6 μg one inhalation bid for maintenance plus additional inhalations as needed; B) Foster® 100/6 μg one inhalation bid for maintenance plus salbutamol as needed.

  • And subsequent visits taking place at clinics after 4 (V3), after 12 (V4), after 24 (V5), after 36 (V6) and after 48 weeks (V7) of treatment.

The total study duration per participant was 50 weeks, including the 2-week run-in period, 48-week treatment phase.

Salbutamol was used as a rescue medication.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Maintenance and Reliever Treatment
  • MART
  • Foster
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written signed and dated obtained from patient;
  2. Male or female patients aged ≥ 18 years;
  3. Clinical diagnosis of asthma for ≥ 6 months;
  4. A positive reversibility test, defined as an increase of at least 12% and at least 200 mL from pre-dose in 30 minutes following 4 puffs (4 × 100 μg) of inhaled salbutamol pMDI. If this could not be achieved, a documented reversibility test to salbutamol within the last 6 months was acceptable for eligibility;
  5. Patients who experienced at least one severe exacerbation in the 12 months before entry (but not in the last month), defined as deterioration in asthma resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic for at least 3 days because of asthma;
  6. Using inhaled corticosteroids (ICS) in monotherapy or using ICS in a fixed or free combination with long acting β2 agonists (LABA) at a constant dose (changes in doses for less than seven days were accepted) for two months before V1.

    • If patients were under ICS only, the daily dose had to be ≥ non-extrafine 1000 μg BDP or equivalent.
    • If patients were under ICS + LABA, the ICS daily dose had to be ≥ non-extrafine 500 μg BDP or equivalent. LABA were to be stopped at least 24 hours before V1.
  7. Not fully controlled asthmatics (which means partly controlled or/and uncontrolled patients according to GINA guidelines 2007) (apart from asthma exacerbation criteria) in the last month before V1.

    Asthma control was assessed in terms of:

    • Daytime symptoms (more than twice a week);
    • Limitation of activities (any);
    • Nocturnal symptoms/awakening (any);
    • Need for rescue (more than twice a week);
    • Forced expiratory volume in the first second (FEV1) \< 80% predicted (or personal best, if known) on any day.

    Partly controlled patients were those with at least one of the above mentioned symptoms/signs in any week of the last month before V1.

    Uncontrolled patients were those with 3 or more features of partly controlled asthma present in any week of the last month before V1.

  8. FEV1 ≥ 60% of predicted for the patient normal value;
  9. Non smokers or ex-smokers (defined as those who have stopped smoking for more than one year and with a smoking history of less than 10 pack/years); Pack/year: number of cigarettes smoked per day multiplied by the number of years of smoking/20.
  10. A co-operative attitude and ability to be trained to correctly use the pMDI;
  11. Subjects who were willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Not fully controlled asthma (defined according to criterion No. 7) in the last week of the run-in was to be confirmed at Visit 2.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum human chorionic gonadotrophin laboratory test (> 5 mIU/mL). Women of , defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means, unless they met the following definition of : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or were using one or more of the following acceptable methods of :

    1. Surgical sterilization (e.g. bilateral tubal ligation, hysterectomy);
    2. Hormonal contraception (implantable, patch, oral);
    3. Double-barrier methods (any double combination of: IUD, male or female condom, diaphragm, sponge, cervical cap).

    Acceptable methods of contraception could include total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensured compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal were not acceptable methods of contraception. Reliable contraception should be maintained throughout the study and for 30 days after study drug discontinuation;

  2. (BMI) > 34 kg/m2;
  3. Patients with lower respiratory tract infections affecting the patient's asthma within 30 days of the screening visit;
  4. Use of systemic in the last month;
  5. Patients with other lung diseases such as (but not limited to) , cystic fibrosis, interstitial lung diseases or any other clinically or functionally significant lung disorder;
  6. Patients who had an uncontrolled respiratory, haematological, immunologic, renal, neurologic, hepatic, endocrinal or other disease, or any condition that could, in the judgment of the investigator, represent for the patients an undue risk or that could compromise the results or interpretation of the study;
  7. History or current evidence of uncontrolled heart failure, coronary artery disease, recent myocardial infarction, severe hypertension, uncontrolled cardiac arrhythmias;
  8. Cancer or any other chronic disease with poor prognosis (less than 2 years) and /or affecting patient status;
  9. Clinically relevant laboratory abnormalities such as (but not limited to) hypokaliemia (\<3.5 mEq/L), that could compromise patient's safety or compliance, interfere with evaluation, or preclude completion of the study, in the judgment of the investigator. Patients with uncontrolled diabetes, including patients with a history of serum glucose levels consistently out of the normal range (> 140 mg/dl) or > 8.0%, were to be excluded from the study;
  10. Patients who had an abnormal interval value in the screening visit test (i.e., > 450 msec in males or > 470 msec in females);
  11. Intolerance or to treatment with β2-agonists and/or ICS or allergy to any component of the study treatments;
  12. Patients treated with slow-release corticosteroids in the 3 months prior to screening visit;
  13. Patients unlikely to comply with the study protocol or unable to understand the nature and scope of the study or the possible benefits or unwanted effects of the study treatments;
  14. Patients being treated with anti-IgE antibodies;
  15. Patients treated with LABA or ICS/LABA fixed combination in the 24 hours before visit 1;
  16. Patients having received an drug within 2 months before the screening visit;
  17. Inability to comply to study procedures or to study treatment intake;
  18. Inability to carry out a valid spirometry;
  19. Severe asthma exacerbation in the last month before screening visit;
  20. Severe asthma exacerbation during the run-in period.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,714 participants (actual)

Study arms

  • Experimental
    Foster (Treatment A)

    Participants received one inhalation of Foster (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose) administered via a pMDI, BID, as maintenance therapy and additional inhalations of Foster (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose) as needed in response to symptoms as reliever therapy. A maximum of 6 inhalations per day was allowed as reliever therapy. To ensure blinding, participants received inhalations of placebo matching Ventolin as reliever therapy. Participants received treatment for a duration of 48 weeks.

    Drug: Beclomethasone dipropionate + Formoterol

  • Active comparator
    Foster + Ventolin (Treatment B)

    Participants received one inhalation of Foster (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose) administered via a pMDI, BID, as maintenance therapy and additional inhalations of Ventolin (Salbutamol, 100 μg per metered dose) as needed in response to symptoms as reliever therapy. A maximum of 6 inhalations per day was allowed as reliever therapy. To ensure blinding, participants received inhalations of placebo matching Foster as reliever therapy. Participants received treatment for a duration of 48 weeks.

    Drug: Salbutamol · Drug: Beclomethasone dipropionate + Formoterol

Interventions

  • Administered via a pressurized metered-dose inhaler

    Also known as: Ventolin

  • DrugBeclomethasone dipropionate + Formoterol

    Drug pages: Beclomethasone · Formoterol

    Administered via a pressurized metered-dose inhaler

    Also known as: Foster

06

What researchers measure

Primary outcomes

  1. Time to First Severe Asthma Exacerbation

    A severe asthma exacerbation was defined as asthma worsening resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days because of asthma. First severe asthma exacerbation occurred after the first dose of randomised study drug and within end of study was considered for the analysis. Patients without a severe asthma exacerbation or withdrawn before having it, are considered as 'censored' at the last day in the study or at the time of the withdrawal. Since the median time (50th percentile) and the other key percentiles (25th and 75th) were not reached, the median time of first exacerbation is not available (N.A.). So, to provide meaningful information, the cumulative number of patients who experienced a severe exacerbation at the end of each time period was reported separately.

    Time frame: From First IMP dose to week 48 (EOT)

  2. Cumulative Number of Patients With Severe Asthma Exacerbation by Inter-visit (Measured in Weeks)

    A severe asthma exacerbation was defined as asthma worsening resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days because of asthma. First severe asthma exacerbation occurred after the first dose of randomised study drug and within end of study was considered for the analysis. Patients without a severe asthma exacerbation or withdrawn before having it, are considered as 'censored' at the last day in the study or at the time of the withdrawal. As already anticipated in the primary endpoint, since the median time (50th percentile) and the other key percentiles (25th and 75th) were not reached, and the median time of first exacerbation is not available (N.A.), to provide meaningful information, the cumulative number of patients who experienced a severe exacerbation at the end of each time period is here reported.

    Time frame: From First dose to end of each interval: 0-4, 4-12, 12-24, 24-36, 36-48 weeks

Secondary outcomes

  1. Number of Severe Asthma Exacerbations Per 100 Patients Per Year

    A severe asthma exacerbation was defined as asthma worsening, resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days. As per the outcome measure title, the total number of severe exacerbations (this outcome), of hospitalisations/emergency room treatment, of systemic corticosteroids use (other outcomes) is expressed as rate (events per 100 patients per year) and compared between arms. Please note that in case of two close severe asthma exacerbations (start date of a severe asthma exacerbation is less than 10 days from the stop date of the previous severe asthma exacerbation), only the first was counted for the analysis.

    Time frame: First dose to end of the study (Up to 48 Weeks)

  2. Number of Systemic Corticosteroids Courses to Treat Asthma Per 100 Patients Per Year

    Systemic corticosteroids courses to treat asthma started at or after the first dose of randomised study drug and with at least one day from the stop date of a systemic corticosteroids course and the start date of the following one have been considered for analysis. As per the outcome measure title, the total number of severe exacerbations (other outcome), of hospitalisations/emergency room treatment (other outcome), of systemic corticosteroids use (this outcome) is expressed as rate (events per 100 patients per year) and compared between arms.

    Time frame: First dose to end of the study (Up to 48 Weeks)

  3. Number of Hospitalisation/Emergency Room Treatments Due to Asthma Per 100 Patients Per Year

    Hospitalization or emergency room treatment due to asthma started at or after the first dose of randomised study drug was be considered for the analysis. As per the outcome measure title, the total number of severe exacerbations (another outcome), of hospitalisations/emergency room treatment (this outcome), of systemic corticosteroids use (other outcomes) is expressed as rate (events per 100 patients per year) and compared between arms.

    Time frame: From first dose to end of the study (Up to Week 48)

  4. Change From Baseline in Asthma Control Questionnaire (ACQ) Score to Each Visit

    The Asthma Control Questionnaire is a tool used to asses how well a participant asthma is controlled and consists of seven questions scored. On average/in general, during the past week 0 (no impairment), 6 (maximum impairment for symptoms). 1. how often were you woken by your asthma during the night? 2. how bad were your asthma symptoms when you woke up in the morning? 3. how limited were you in your activities because of your asthma? 4. how much shortness of breath did you experience because of your asthma? 5. how much of the time did you wheeze? 6. how many puffs/inhalations of short-acting bronchodilator have you used each day? 7. FEV1 pre-bronchodilator, FEV1 predicted FEV1 % predicted (by clinical staff) The ACQ total score has been calculated as the mean of the seven question scores ranging from 0 (totally controlled) and 6 (severely uncontrolled). Higher scores indicate the worse outcomes. Adjusted means were reported.

    Time frame: Week 4 (V3), Week 12 (V4), Week 24 (V5), Week 36 (V6), Week 48 (V7)

  5. Number of Mild Asthma Exacerbations Per 100 Patients / Year

    A mild asthma exacerbation was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only one mild asthma exacerbation was considered. In case of two close mild asthma exacerbations (start date of a mild asthma exacerbation is less than 7 days from the stop date of the previous mild asthma exacerbation), only the first was counted for the analysis. Mild asthma exacerbations occurred at or after the first dose of randomised study drug and within end of study is considered for the analysis. As per the outcome measure title, the total number of mild asthma exacerbations is expressed as rate (events per 100 patients per year) and compared between arms.

    Time frame: From first dose through end of the study (Up to Week 48)

  6. Number of Mild Asthma Exacerbations: Number of Total Events

    A mild asthma exacerbation was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only one mild asthma exacerbation was considered. In case of two close mild asthma exacerbations (start date of a mild asthma exacerbation is less than 7 days from the stop date of the previous mild asthma exacerbation), only the first was counted for the analysis. Total number of mild asthma exacerbation events were reported. Mild asthma exacerbations occurred at or after the first dose of randomised study drug and within end of study is considered for the analysis. .

    Time frame: From first dose through end of the study (Up to Week 48)

  7. Time to First Mild Asthma Exacerbation

    A "mild asthma exacerbation" was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only 1 mild exacerbation was considered. In case of two close mild exacerbations (start date of a mild exacerbation is less than 7 days from the stop date of the previous mild exacerbation), only the first was counted for the analysis. First mild exacerbation occurred after the first dose of randomised study drug and within end of study is considered for the analysis. In patient with at least one mild exacerbation, the time to first mild exacerbation was calculated as the time in days between the first dose of randomised study drug (derived) and the time at which the first mild exacerbation occurs (date of the first day of the first mild exacerbation). Time to first mild asthma exacerbation (days) = (date of first day of first mild exacerbation - date of first dose of randomised study drug (derived)) +1

    Time frame: From first dose to end of the study (Up to Week 48)

  8. Change From Baseline in Morning and Evening Peak Expiratory Flow (PEF) to Each Visit

    PEF is measured twice a day (morning and evening) with Spirotel, a portable electronic peak flow meter. PEF measurement recorded in the morning of the day of each clinic visit was considered as data of the period before clinic visit. During each measurement session (morning or evening before the intake of the study medication) the participant performed 3 blows and only the best PEF parameter was saved into the Spirotel memory.

    Time frame: Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)

  9. Change From Baseline in Daily PEF Variability to Each Visit

    PEF is measured twice a day (morning and evening) with Spirotel. PEF measurement recorded in the morning of the day of each clinic visit was considered as data of the period before clinic visit. During each measurement session (morning or evening before the intake of the study medication) the participant will perform 3 blows and only the best PEF parameter will be saved into the Spirotel memory. The variability of PEF of a day will be calculated using the Best PEF morning and the Best PEF evening recorded in the same day. Variability of PEF is measured daily with Spirotel using the following formula: Best PEF evening - Best PEF morning/Best PEF evening + Best PEF morning/2 X 100

    Time frame: Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)

  10. Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Each Visit

    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using spirometry, conducted at baseline and all clinical visits. An increase in FEV1 reflects improved airway patency, while a decrease suggests worsening obstruction. Higher FEV1 values indicate better lung function. Adjusted means were reported.

    Time frame: Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)

  11. Change From Baseline in Pre-Dose Forced Expiratory Flow Between 25% and 75% of Vital Capacity (FEF25-75%) at Each Visit

    FEF is a lung function test and is measured using the spirometery. The FEF25%-75% is the forced expiratory flow from 25% to 75% of FVC. FEF25%-75% measurement is conducted at baseline and all clinical visits. An increase in FEF25%-75% reflects improved airway patency, while a decrease suggests worsening obstruction. Higher FEF25%-75% values indicate better lung function. Adjusted means were reported.

    Time frame: Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)

  12. Change From Baseline in Total Asthma Symptom Scores Measured Daily by Each Visit

    The asthma symptoms are: cough, wheeze, chest tightness and breathlessness. Each morning and evening asthma symptoms are to be scored, as respectively occurred during the night and during the day, as follows: Night-time asthma symptom score: 0 = No symptom, 1 = Mild: symptoms not causing awakening, 2 = Moderate: discomfort enough to cause awakening, 3 = Severe: causing awakening for most of the night / do not allow to sleep at all Day-time asthma symptom score: 0 = No symptom, 1 = Mild: aware of symptoms which can be easily tolerated, 2 = Moderate: discomfort enough to cause interference with daily activity, 3 = Severe: incapacitating with inability to work / take part in usual activity Total asthma symptoms score was calculated as the sum of the day-time and the night-time asthma symptoms score recorded on the following day and score ranges from 0 to 6, higher score indicates worse symptoms.

    Time frame: Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)

  13. Number of Inhalations of Reliever Medication Per Day by Each Two-Week Period

    The daily use of reliever medication was calculated as sum of the number of puffs taken during the day and the number of puffs taken during the night recorded on the following day. In case one session in a day is missing, only the available session (evening or morning) was considered for the daily use of reliever medication. A minimum of seven evaluable measurements are required in each two-week treatment period and during the two-weeks of the run-in period (baseline).

    Time frame: Weeks 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18,19-20,21-22, 23-24, 25-26, 27-28, 29-30, 31-32, 33-34, 35-36, 37-38, 39-40, 41-42, 43-44, 45-46, 47-48

  14. Percentage of Asthma Symptom-free Days by Each Two-Week Period

    Asthma symptom-free days are days with the total asthma symptom score equal to zero. Percentage of asthma symptom-free days will be calculated in each two-week period using the following formula: % of asthma symptoms- free days = Number o f asthma symptoms- free days in that two - week period/Number o f days with data recorded for asthma symptom scores in that two - week period X 100.

    Time frame: Week 3-4, 11-12, 23-24, 35-36 and 47-48

  15. Percentage of Reliever-Medication-Free Days by Each Two-Week Period

    A day without reliever medication is a day in which the number of puffs of reliever medication taken in the 24 hours is zero. A day will be considered as missing if both measurements (evening and morning) are missing. A day will be considered as "not-free" if one session is recorded and the other is missing. Percentage of reliever medication-free days will be calculated in each two-week period using the following formula: % of reliever medication-free days = Number of reliever medication-free days in that two -week period/Number of days with data recorded for reliever medication in that two -week period X 100

    Time frame: Weeks 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18,19-20,21-22, 23-24, 25-26, 27-28, 29-30, 31-32, 33-34, 35-36, 37-38, 39-40, 41-42, 43-44, 45-46, 47-48

  16. Percentage of Asthma Control Days by Each Two-week Period Before Clinic Visits

    Asthma control day is a day with total asthma symptom score equal to zero and without use of reliever medication. A day will be considered as missing if both measurements (evening and morning) are missing. A day will be considered as "not control" if one session is recorded and the other is missing. Percentage of asthma control days will be calculated in each two-week period using the following formula: % of asthma control days = Number of asthma control days in that two -week period/Number of days with data recorded for asthma symptom scores and reliever medication in that two-week period X100

    Time frame: Week 3-4, 11-12, 23-24, 35-36 and 47-48

  17. Number of Participants With Treatment Emergent Adverse Events

    AE=An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. Serious AE= An adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. ADR=A response to a medicinal product which is harmful and unintended. Response in this context means that a causal relationship between the medicinal product and an adverse event is at least a reasonable possibility Serious ADR=An adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. Severe AE= "Severe" refers to the intensity of an AE; the event itself may be of relatively minor medical significance but intense.

    Time frame: From first dose of study drug until end of the study (up to 48 weeks)

  18. Number of Patients Who Required > 6 Rescue Inhalations Per Day for at Least Two Consecutive Days During During Treatment Period

    Use of reliever medication was derived from the data of SpirotelTM. The event "more than six reliever medications per day for two consecutive days" is defined as at least two consecutive days with more than six puffs of reliever medication in the day.

    Time frame: From first dose of study drug until end of the study (up to 48 weeks)

07

Results

Posted May 7, 2026

Participant flow

Participants were enrolled across 183 centers in 14 countries. A total of 2079 participants were screened for eligibility, 365 participants were screen failure and 1714 of them were enrolled and randomised in this study.

Participant flow — Overall Study
MilestoneFoster (Treatment A)Foster + Ventolin (Treatment B)
Started857857
Randomized population857857
Safety population854854
Intent-to-treat population852849
Completed758748
Not completed99109
Withdrew: Adverse event1018
Withdrew: Lack of therapeutic response25
Withdrew: Lost to follow-up108
Withdrew: Protocol violation3127
Withdrew: Poor compliance to study drug1311
Withdrew: Death12
Withdrew: Withdrawal by subject2834
Withdrew: Miscellaneous44

Outcome measures

PrimaryTime to First Severe Asthma Exacerbation

A severe asthma exacerbation was defined as asthma worsening resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days because of asthma. First severe asthma exacerbation occurred after the first dose of randomised study drug and within end of study was considered for the analysis. Patients without a severe asthma exacerbation or withdrawn before having it, are considered as 'censored' at the last day in the study or at the time of the withdrawal. Since the median time (50th percentile) and the other key percentiles (25th and 75th) were not reached, the median time of first exacerbation is not available (N.A.). So, to provide meaningful information, the cumulative number of patients who experienced a severe exacerbation at the end of each time period was reported separately.

Time frame:
From First IMP dose to week 48 (EOT)
Reported as:
Median · weeks
Time to First Severe Asthma Exacerbation
weeksTreatment ATreatment B
Time to First Severe Asthma ExacerbationNA (NA to NA)NA (NA to NA)
PrimaryCumulative Number of Patients With Severe Asthma Exacerbation by Inter-visit (Measured in Weeks)

A severe asthma exacerbation was defined as asthma worsening resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days because of asthma. First severe asthma exacerbation occurred after the first dose of randomised study drug and within end of study was considered for the analysis. Patients without a severe asthma exacerbation or withdrawn before having it, are considered as 'censored' at the last day in the study or at the time of the withdrawal. As already anticipated in the primary endpoint, since the median time (50th percentile) and the other key percentiles (25th and 75th) were not reached, and the median time of first exacerbation is not available (N.A.), to provide meaningful information, the cumulative number of patients who experienced a severe exacerbation at the end of each time period is here reported.

Time frame:
From First dose to end of each interval: 0-4, 4-12, 12-24, 24-36, 36-48 weeks
Reported as:
Number · no. of patients with exacerbation
Cumulative Number of Patients With Severe Asthma Exacerbation by Inter-visit (Measured in Weeks)
no. of patients with exacerbationTreatment ATreatment B
weeks 0-41118
weeks 4-123256
weeks 12-2470103
weeks 24-2690132
weeks 36-48 (EoT)99152
Statistical analysis
  • Treatment A vs Treatment B · Log Rank · p = <0.001
  • Treatment A vs Treatment B · Cox proportional hazards model · p = <0.001 · Hazard ratio (hr): 0.636 · 95% CI 0.494 to 0.820Cox proportional hazards regression model with treatment and country as factors included in the model
SecondaryNumber of Severe Asthma Exacerbations Per 100 Patients Per Year

A severe asthma exacerbation was defined as asthma worsening, resulting in hospitalization or emergency room treatment due to asthma worsening, or the need for systemic steroids for ≥ 3 days. As per the outcome measure title, the total number of severe exacerbations (this outcome), of hospitalisations/emergency room treatment, of systemic corticosteroids use (other outcomes) is expressed as rate (events per 100 patients per year) and compared between arms. Please note that in case of two close severe asthma exacerbations (start date of a severe asthma exacerbation is less than 10 days from the stop date of the previous severe asthma exacerbation), only the first was counted for the analysis.

Time frame:
First dose to end of the study (Up to 48 Weeks)
Reported as:
Number · events per 100 patients per year
Number of Severe Asthma Exacerbations Per 100 Patients Per Year
events per 100 patients per yearTreatment ATreatment B
Number of Severe Asthma Exacerbations Per 100 Patients Per Year17.6126.77
Statistical analysis
  • Treatment A vs Treatment B · Poisson regression model · p = <0.001 (Poisson regression model with number of severe asthma exacerbations as dependent variable, treatment \& country as factors. Log-time on study has been used as an offset.) · Rate ratio: 0.659 · 95% CI 0.546 to 0.796The overdispersion parameter was considered in order to account for between-patient variability in the severe asthma exacerbation rate.
SecondaryNumber of Systemic Corticosteroids Courses to Treat Asthma Per 100 Patients Per Year

Systemic corticosteroids courses to treat asthma started at or after the first dose of randomised study drug and with at least one day from the stop date of a systemic corticosteroids course and the start date of the following one have been considered for analysis. As per the outcome measure title, the total number of severe exacerbations (other outcome), of hospitalisations/emergency room treatment (other outcome), of systemic corticosteroids use (this outcome) is expressed as rate (events per 100 patients per year) and compared between arms.

Time frame:
First dose to end of the study (Up to 48 Weeks)
Reported as:
Number · Courses per 100 patients per year
Number of Systemic Corticosteroids Courses to Treat Asthma Per 100 Patients Per Year
Courses per 100 patients per yearTreatment ATreatment B
Number of Systemic Corticosteroids Courses to Treat Asthma Per 100 Patients Per Year16.9325.95
Statistical analysis
  • Treatment A vs Treatment B · Poisson regression model · p = <0.001 (Poisson regression model with number of systemic corticosteroids courses to treat asthma as dependent variable, treatment and country as factors. Log-time on study has been used as an offset.) · Rate ratio: 0.654 · 95% CI 0.538 to 0.794The overdispersion parameter is considered in order to account for between-patient variability in the systemic corticosteroids courses rate.
SecondaryNumber of Hospitalisation/Emergency Room Treatments Due to Asthma Per 100 Patients Per Year

Hospitalization or emergency room treatment due to asthma started at or after the first dose of randomised study drug was be considered for the analysis. As per the outcome measure title, the total number of severe exacerbations (another outcome), of hospitalisations/emergency room treatment (this outcome), of systemic corticosteroids use (other outcomes) is expressed as rate (events per 100 patients per year) and compared between arms.

Time frame:
From first dose to end of the study (Up to Week 48)
Reported as:
Number · events x 100 patients x year
Number of Hospitalisation/Emergency Room Treatments Due to Asthma Per 100 Patients Per Year
events x 100 patients x yearTreatment ATreatment B
Number of Hospitalisation/Emergency Room Treatments Due to Asthma Per 100 Patients Per Year9.0813.52
Statistical analysis
  • Treatment A vs Treatment B · Poisson regression model · p = <0.001 (Analysis is based on a Poisson regression model with number of hospitalizations or emergency room treatment due to asthma as dependent variable, treatment and country as factors. Log-time on study has been used as an offset.) · Rate ratio: 0.654 · 95% CI 0.538 to 0.794The overdispersion parameter is considered in order to account for between-patient variability in hospitalizations or emergency room treatment rate.
SecondaryChange From Baseline in Asthma Control Questionnaire (ACQ) Score to Each Visit

The Asthma Control Questionnaire is a tool used to asses how well a participant asthma is controlled and consists of seven questions scored. On average/in general, during the past week 0 (no impairment), 6 (maximum impairment for symptoms). 1. how often were you woken by your asthma during the night? 2. how bad were your asthma symptoms when you woke up in the morning? 3. how limited were you in your activities because of your asthma? 4. how much shortness of breath did you experience because of your asthma? 5. how much of the time did you wheeze? 6. how many puffs/inhalations of short-acting bronchodilator have you used each day? 7. FEV1 pre-bronchodilator, FEV1 predicted FEV1 % predicted (by clinical staff) The ACQ total score has been calculated as the mean of the seven question scores ranging from 0 (totally controlled) and 6 (severely uncontrolled). Higher scores indicate the worse outcomes. Adjusted means were reported.

Time frame:
Week 4 (V3), Week 12 (V4), Week 24 (V5), Week 36 (V6), Week 48 (V7)
Reported as:
Mean · score on a scale
Change From Baseline in Asthma Control Questionnaire (ACQ) Score to Each Visit
score on a scaleTreatment ATreatment B
Week 4 (Visit 3)-0.217 (-0.263 to -0.170)-0.198 (-0.244 to -0.151)
Week 12 (Visit 4)-0.289 (-0.340 to -0.238)-0.258 (-0.309 to -0.207)
Week 24 (Visit 5)-0.328 (-0.382 to -0.273)-0.325 (-0.380 to -0.271)
Week 36 (Visit 6)-0.410 (-0.466 to -0.354)-0.373 (-0.429 to -0.317)
Week 48 (Visit 7)-0.480 (-0.536 to -0.423)-0.423 (-0.480 to -0.367)
Statistical analysis
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.522 (Mixed model for repeated measures with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: -0.019 · 95% CI -0.078 to 0.040An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.358 (Mixed model for repeated measures with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: -0.031 · 95% CI -0.097 to 0.035An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.948 (Mixed model for repeated measures with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: -0.002 · 95% CI -0.073 to 0.069An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.330 (Mixed model for repeated measures with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: -0.036 · 95% CI -0.110 to 0.037An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.137 (Mixed model for repeated measures with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: -0.056 · 95% CI -0.130 to 0.018An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
SecondaryNumber of Mild Asthma Exacerbations Per 100 Patients / Year

A mild asthma exacerbation was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only one mild asthma exacerbation was considered. In case of two close mild asthma exacerbations (start date of a mild asthma exacerbation is less than 7 days from the stop date of the previous mild asthma exacerbation), only the first was counted for the analysis. Mild asthma exacerbations occurred at or after the first dose of randomised study drug and within end of study is considered for the analysis. As per the outcome measure title, the total number of mild asthma exacerbations is expressed as rate (events per 100 patients per year) and compared between arms.

Time frame:
From first dose through end of the study (Up to Week 48)
Reported as:
Number · events per 100 patients per year
Number of Mild Asthma Exacerbations Per 100 Patients / Year
events per 100 patients per yearTreatment ATreatment B
Number of Mild Asthma Exacerbations Per 100 Patients / Year385.65380.99
Statistical analysis
  • Treatment A vs Treatment B · Poisson regression model · p = 0.799 (Poisson regression model with number of mild asthma exacerbations as dependent variable, treatment and country as factors. Log-time on study has been used as an offset.) · Rate ratio: 1.013 · 95% CI 0.915 to 1.123The over dispersion parameter is considered in order to account for between-patient variability in the mild asthma exacerbation rate.
SecondaryNumber of Mild Asthma Exacerbations: Number of Total Events

A mild asthma exacerbation was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only one mild asthma exacerbation was considered. In case of two close mild asthma exacerbations (start date of a mild asthma exacerbation is less than 7 days from the stop date of the previous mild asthma exacerbation), only the first was counted for the analysis. Total number of mild asthma exacerbation events were reported. Mild asthma exacerbations occurred at or after the first dose of randomised study drug and within end of study is considered for the analysis. .

Time frame:
From first dose through end of the study (Up to Week 48)
Reported as:
Number · Number of Events
Number of Mild Asthma Exacerbations: Number of Total Events
Number of EventsTreatment ATreatment B
Number of Mild Asthma Exacerbations: Number of Total Events28472789
SecondaryTime to First Mild Asthma Exacerbation

A "mild asthma exacerbation" was defined as two consecutive mild asthma exacerbation days satisfying the same criterion. In case periods satisfying different criteria overlapping, only 1 mild exacerbation was considered. In case of two close mild exacerbations (start date of a mild exacerbation is less than 7 days from the stop date of the previous mild exacerbation), only the first was counted for the analysis. First mild exacerbation occurred after the first dose of randomised study drug and within end of study is considered for the analysis. In patient with at least one mild exacerbation, the time to first mild exacerbation was calculated as the time in days between the first dose of randomised study drug (derived) and the time at which the first mild exacerbation occurs (date of the first day of the first mild exacerbation). Time to first mild asthma exacerbation (days) = (date of first day of first mild exacerbation - date of first dose of randomised study drug (derived)) +1

Time frame:
From first dose to end of the study (Up to Week 48)
Reported as:
Median · weeks
Time to First Mild Asthma Exacerbation
weeksTreatment ATreatment B
Time to First Mild Asthma Exacerbation11.43 (9.43 to 12.9)9.57 (7.86 to 11.3)
Statistical analysis
  • Treatment A vs Treatment B · Log Rank · p = 0.581
  • Treatment A vs Treatment B · Cox proportional hazards model · p = 0.565 (Analysis is based on a Cox proportional hazard regression model with treatment and country as factors.) · Hazard ratio (hr): 0.967 · 95% CI 0.864 to 1.083
SecondaryChange From Baseline in Morning and Evening Peak Expiratory Flow (PEF) to Each Visit

PEF is measured twice a day (morning and evening) with Spirotel, a portable electronic peak flow meter. PEF measurement recorded in the morning of the day of each clinic visit was considered as data of the period before clinic visit. During each measurement session (morning or evening before the intake of the study medication) the participant performed 3 blows and only the best PEF parameter was saved into the Spirotel memory.

Time frame:
Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)
Reported as:
Mean · Liters per minute
Change From Baseline in Morning and Evening Peak Expiratory Flow (PEF) to Each Visit
Liters per minuteTreatment ATreatment B
Morning PEF: Week 4 (Visit 3)2.40 ± 41.2-3.53 ± 37.3
Morning PEF: week 12 (Visit 4)-0.16 ± 45.8-11.5 ± 43.7
Morning PEF: week 24 (Visit 5)-4.01 ± 52.9-13.8 ± 46.1
Morning PEF: Week 36 (Visit 6)-5.83 ± 54.6-8.71 ± 54.1
Morning PEF: Week 48 (Visit 7)-7.48 ± 54.4-9.70 ± 52.7
Evening PEF: Week 4 (Visit 3)0.69 ± 40.6-4.32 ± 36.9
Evening PEF: Week 12 (Visit 4)-2.54 ± 45.4-12.4 ± 42.3
Evening PEF: week 24 (Visit 5)-7.36 ± 48.8-15.2 ± 47.7
Evening PEF: week 36 (Visit 6)-7.20 ± 54.4-14.7 ± 51.4
Evening PEF: week 48 (Visit 7)-10.7 ± 57.2-16.8 ± 52.6
Statistical analysis
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.018 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 5.861 · 95% CI 1.012 to 10.710An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = <0.001 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 10.229 · 95% CI 4.616 to 15.843An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.003 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 9.530 · 95% CI 3.207 to 15.853An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.193 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 0.193 · 95% CI -2.371 to 11.757An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.315 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 3.688 · 95% CI -3.506 to 10.882An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.129 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 3.675 · 95% CI -1.074 to 8.424An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.005 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 7.864 · 95% CI 2.404 to 13.325An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.110 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 4.971 · 95% CI -1.131 to 11.072An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.076 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 6.124 · 95% CI -0.633 to 12.880An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.305 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 3.724 · 95% CI -3.392 to 10.839An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
SecondaryChange From Baseline in Daily PEF Variability to Each Visit

PEF is measured twice a day (morning and evening) with Spirotel. PEF measurement recorded in the morning of the day of each clinic visit was considered as data of the period before clinic visit. During each measurement session (morning or evening before the intake of the study medication) the participant will perform 3 blows and only the best PEF parameter will be saved into the Spirotel memory. The variability of PEF of a day will be calculated using the Best PEF morning and the Best PEF evening recorded in the same day. Variability of PEF is measured daily with Spirotel using the following formula: Best PEF evening - Best PEF morning/Best PEF evening + Best PEF morning/2 X 100

Time frame:
Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)
Reported as:
Mean · Liters per minute
Change From Baseline in Daily PEF Variability to Each Visit
Liters per minuteTreatment ATreatment B
Weeks 4 (Visit 3)-0.29 ± 4.610.21 ± 5.08
Weeks 12 (Visit 4)-0.36 ± 4.93-0.38 ± 5.54
Weeks 24 (Visit 5)-0.49 ± 5.12-0.044 ± 6.21
Weeks 36 (Visit 6)-0.42 ± 5.21-0.24 ± 6.05
Weeks 48 (Visit 7)-0.017 ± 5.06-0.88 ± 6.29
Statistical analysis
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.200 (MMRM with change from baseline to each inter-visit period as dependent variable, treatment, period, treatment x period interaction, sex and country as fixed effects, baseline and baseline x period interaction as covariates.) · Adjusted mean difference: -0.513 · 95% CI -1.298 to 0.272An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.813 (MMRM with change from baseline to each inter-visit period as dependent variable, treatment, period, treatment x period interaction, sex and country as fixed effects, baseline and baseline x period interaction as covariates.) · Adjusted mean difference: 0.105 · 95% CI -0.763 to 0.972An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.391 (MMRM with change from baseline to each inter-visit period as dependent variable, treatment, period, treatment x period interaction, sex and country as fixed effects, baseline and baseline x period interaction as covariates.) · Adjusted mean difference: -0.439 · 95% CI -1.443 to 0.565An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.698 (MMRM with change from baseline to each inter-visit period as dependent variable, treatment, period, treatment x period interaction, sex and country as fixed effects, baseline and baseline x period interaction as covariates.) · Adjusted mean difference: -0.201 · 95% CI -1.219 to 0.817An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.407 (MMRM with change from baseline to each inter-visit period as dependent variable, treatment, period, treatment x period interaction, sex and country as fixed effects, baseline and baseline x period interaction as covariates.) · Adjusted mean difference: 0.406 · 95% CI -0.556 to 1.369An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
SecondaryChange From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Each Visit

FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured using spirometry, conducted at baseline and all clinical visits. An increase in FEV1 reflects improved airway patency, while a decrease suggests worsening obstruction. Higher FEV1 values indicate better lung function. Adjusted means were reported.

Time frame:
Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)
Reported as:
Mean · Litres
Change From Baseline in Pre-Dose Forced Expiratory Volume in the First Second (FEV1) at Each Visit
LitresTreatment ATreatment B
Week 4 (Visit 3)0.09 ± 0.340.08 ± 0.36
Week 12(Visit 4)0.11 ± 0.360.09 ± 0.38
Week 24 (Visit 5)0.11 ± 0.380.10 ± 0.42
Week 36 (Visit 6)0.12 ± 0.390.11 ± 0.42
Week 48 (Visit 7)0.11 ± 0.390.11 ± 0.43
Statistical analysis
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.575 (MMRM with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 0.009 · 95% CI -0.024 to 0.042An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.408 (MMRM with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 0.015 · 95% CI -0.021 to 0.051An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.451 (MMRM with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 0.015 · 95% CI -0.024 to 0.054An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.487 (MMRM with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 0.014 · 95% CI -0.026 to 0.054An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.969 (MMRM with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 0.001 · 95% CI -0.039 to 0.041An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
SecondaryChange From Baseline in Pre-Dose Forced Expiratory Flow Between 25% and 75% of Vital Capacity (FEF25-75%) at Each Visit

FEF is a lung function test and is measured using the spirometery. The FEF25%-75% is the forced expiratory flow from 25% to 75% of FVC. FEF25%-75% measurement is conducted at baseline and all clinical visits. An increase in FEF25%-75% reflects improved airway patency, while a decrease suggests worsening obstruction. Higher FEF25%-75% values indicate better lung function. Adjusted means were reported.

Time frame:
Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)
Reported as:
Mean · Liters per Second
Change From Baseline in Pre-Dose Forced Expiratory Flow Between 25% and 75% of Vital Capacity (FEF25-75%) at Each Visit
Liters per SecondTreatment ATreatment B
Week 4 (Visit 3)0.09 ± 0.560.07 ± 0.57
Week 12 (Visit 4)0.09 ± 0.580.07 ± 0.62
Week 24 (Visit 5)0.07 ± 0.660.06 ± 0.63
Week 36 (Visit 6)0.10 ± 0.700.07 ± 0.65
Week 48 (Visit 7)0.06 ± 0.610.06 ± 0.68
Statistical analysis
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.685 (MMRM with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 0.011 · 95% CI -0.042 to 0.064An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.515 (MMRM with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 0.019 · 95% CI -0.038 to 0.076An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.960 (MMRM with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 0.002 · 95% CI -0.061 to 0.064An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.450 (MMRM with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: 0.025 · 95% CI -0.041 to 0.091An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.596 (MMRM with change from baseline at each visit as dependent variable, treatment, visit, treatment x visit interaction and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: -0.017 · 95% CI -0.080 to 0.046An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
SecondaryChange From Baseline in Total Asthma Symptom Scores Measured Daily by Each Visit

The asthma symptoms are: cough, wheeze, chest tightness and breathlessness. Each morning and evening asthma symptoms are to be scored, as respectively occurred during the night and during the day, as follows: Night-time asthma symptom score: 0 = No symptom, 1 = Mild: symptoms not causing awakening, 2 = Moderate: discomfort enough to cause awakening, 3 = Severe: causing awakening for most of the night / do not allow to sleep at all Day-time asthma symptom score: 0 = No symptom, 1 = Mild: aware of symptoms which can be easily tolerated, 2 = Moderate: discomfort enough to cause interference with daily activity, 3 = Severe: incapacitating with inability to work / take part in usual activity Total asthma symptoms score was calculated as the sum of the day-time and the night-time asthma symptoms score recorded on the following day and score ranges from 0 to 6, higher score indicates worse symptoms.

Time frame:
Baseline, Weeks 4 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7)
Reported as:
Mean · score on a scale
Change From Baseline in Total Asthma Symptom Scores Measured Daily by Each Visit
score on a scaleTreatment ATreatment B
Week 4 (Visit 3)-0.78 ± 3.20-0.70 ± 3.64
Week 12 (Visit 4)-1.14 ± 3.83-1.01 ± 4.28
Week 24 (Visit 5)-1.54 ± 4.06-1.17 ± 4.78
Week 36 (Visit 6)-1.61 ± 4.11-1.40 ± 4.78
Week 48 (Visit 7)-1.67 ± 4.19-1.67 ± 4.77
Statistical analysis
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.942 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: -0.012 · 95% CI -0.339 to 0.314An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.792 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: -0.052 · 95% CI -0.438 to 0.334An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.433 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates) · Adjusted mean difference: -0.170 · 95% CI -0.594 to 0.254An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.584 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: -0.123 · 95% CI -0.562 to 0.316An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
  • Treatment A vs Treatment B · Mixed Models Analysis · p = 0.507 (MMRM with change from baseline to two-week period before clinic visits as dependent variable, treatment, visit, treatment x visit interaction, sex and country as fixed effects, baseline and baseline x visit interaction as covariates.) · Adjusted mean difference: -0.152 · 95% CI -0.600 to 0.297An unstructured covariance matrix for each patient has been considered and the Kenward-Roger adjustment has been used for the degrees of freedom.
SecondaryNumber of Inhalations of Reliever Medication Per Day by Each Two-Week Period

The daily use of reliever medication was calculated as sum of the number of puffs taken during the day and the number of puffs taken during the night recorded on the following day. In case one session in a day is missing, only the available session (evening or morning) was considered for the daily use of reliever medication. A minimum of seven evaluable measurements are required in each two-week treatment period and during the two-weeks of the run-in period (baseline).

Time frame:
Weeks 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18,19-20,21-22, 23-24, 25-26, 27-28, 29-30, 31-32, 33-34, 35-36, 37-38, 39-40, 41-42, 43-44, 45-46, 47-48
Reported as:
Mean · Inhalations per day
Number of Inhalations of Reliever Medication Per Day by Each Two-Week Period
Inhalations per dayTreatment ATreatment B
Week 1-21.00 ± 1.360.99 ± 1.39
Week 3-41.00 ± 1.420.96 ± 1.45
Week 5-60.96 ± 1.300.95 ± 1.39
Week 7-80.97 ± 1.380.92 ± 1.36
Week 9-100.95 ± 1.370.91 ± 1.44
Week 11-120.94 ± 1.360.88 ± 1.39
Week 13-140.93 ± 1.320.88 ± 1.37
Week 15-160.94 ± 1.320.89 ± 1.41
Week 17-180.90 ± 1.280.84 ± 1.34
Week 19-200.90 ± 1.290.83 ± 1.33
Week 21-220.91 ± 1.330.86 ± 1.35
Week 23-240.90 ± 1.320.85 ± 1.33
Week 25-260.85 ± 1.240.82 ± 1.31
Week 27-280.85 ± 1.250.78 ± 1.27
Week 29-300.84 ± 1.230.79 ± 1.31
Week 31-320.84 ± 1.270.79 ± 1.30
Week 33-340.82 ± 1.210.75 ± 1.28
Week 35-360.78 ± 1.160.74 ± 1.24
Week 37-380.77 ± 1.220.70 ± 1.16
Week 39-400.79 ± 1.220.71 ± 1.21
Week 41-420.76 ± 1.180.71 ± 1.18
Week 43-440.79 ± 1.240.70 ± 1.17
Week 45-460.77 ± 1.200.71 ± 1.20
Week 47-480.75 ± 1.140.71 ± 1.21
SecondaryPercentage of Asthma Symptom-free Days by Each Two-Week Period

Asthma symptom-free days are days with the total asthma symptom score equal to zero. Percentage of asthma symptom-free days will be calculated in each two-week period using the following formula: % of asthma symptoms- free days = Number o f asthma symptoms- free days in that two - week period/Number o f days with data recorded for asthma symptom scores in that two - week period X 100.

Time frame:
Week 3-4, 11-12, 23-24, 35-36 and 47-48
Reported as:
Mean · percentage of days
Percentage of Asthma Symptom-free Days by Each Two-Week Period
percentage of daysTreatment ATreatment B
Weeks 3-412.5 ± 25.414.4 ± 26.9
Weeks 11-1215.2 ± 28.616.1 ± 28.1
Weeks 23-2416.3 ± 29.019.2 ± 31.5
Weeks 35-3618.8 ± 31.220.7 ± 32.4
Weeks 47-4818.8 ± 30.420.3 ± 32.4
SecondaryPercentage of Reliever-Medication-Free Days by Each Two-Week Period

A day without reliever medication is a day in which the number of puffs of reliever medication taken in the 24 hours is zero. A day will be considered as missing if both measurements (evening and morning) are missing. A day will be considered as "not-free" if one session is recorded and the other is missing. Percentage of reliever medication-free days will be calculated in each two-week period using the following formula: % of reliever medication-free days = Number of reliever medication-free days in that two -week period/Number of days with data recorded for reliever medication in that two -week period X 100

Time frame:
Weeks 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18,19-20,21-22, 23-24, 25-26, 27-28, 29-30, 31-32, 33-34, 35-36, 37-38, 39-40, 41-42, 43-44, 45-46, 47-48
Reported as:
Mean · percentage of days
Percentage of Reliever-Medication-Free Days by Each Two-Week Period
percentage of daysTreatment ATreatment B
Week 1-250.5 ± 37.952.3 ± 37.6
Week 3-449.3 ± 38.252.8 ± 37.5
Week 5-649.2 ± 38.152.5 ± 36.5
Week 7-849.2 ± 38.152.2 ± 37.6
Week 9-1048.8 ± 38.452.9 ± 37.1
Week 11-1248.5 ± 37.752.5 ± 36.7
Week 13-1449.2 ± 38.152.4 ± 36.7
Week 15-1648.0 ± 37.753.0 ± 37.2
Week 17-1848.4 ± 37.652.4 ± 37.2
Week 19-2048.3 ± 37.353.1 ± 36.7
Week 21-2248.7 ± 37.652.6 ± 36.7
Week 23-2447.5 ± 37.052.3 ± 36.4
Week 25-2649.1 ± 36.952.4 ± 36.8
Week 27-2848.7 ± 37.352.3 ± 36.9
Week 29-3048.9 ± 37.153.3 ± 36.9
Week 31-3248.4 ± 37.053.1 ± 37.6
Week 33-3449.2 ± 37.254.0 ± 37.5
Week 35-3649.3 ± 36.653.2 ± 36.4
Week 37-3850.9 ± 37.453.8 ± 36.7
Week 39-4049.6 ± 37.653.6 ± 37.1
Week 41-4249.8 ± 37.653.8 ± 36.6
Week 43-4449.8 ± 37.852.7 ± 36.3
Week 45-4650.2 ± 37.753.8 ± 36.8
Week 47-4848.5 ± 36.552.9 ± 35.4
SecondaryPercentage of Asthma Control Days by Each Two-week Period Before Clinic Visits

Asthma control day is a day with total asthma symptom score equal to zero and without use of reliever medication. A day will be considered as missing if both measurements (evening and morning) are missing. A day will be considered as "not control" if one session is recorded and the other is missing. Percentage of asthma control days will be calculated in each two-week period using the following formula: % of asthma control days = Number of asthma control days in that two -week period/Number of days with data recorded for asthma symptom scores and reliever medication in that two-week period X100

Time frame:
Week 3-4, 11-12, 23-24, 35-36 and 47-48
Reported as:
Mean · percentage of days
Percentage of Asthma Control Days by Each Two-week Period Before Clinic Visits
percentage of daysTreatment ATreatment B
Weeks 3-411.6 ± 24.513.7 ± 26.4
Weeks 11-1214.2 ± 27.915.4 ± 27.5
Weeks 23-2415.4 ± 28.118.2 ± 30.7
Weeks 35-3617.8 ± 30.419.3 ± 31.3
Weeks 47-4817.7 ± 29.319.2 ± 31.6
SecondaryNumber of Participants With Treatment Emergent Adverse Events

AE=An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. Serious AE= An adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. ADR=A response to a medicinal product which is harmful and unintended. Response in this context means that a causal relationship between the medicinal product and an adverse event is at least a reasonable possibility Serious ADR=An adverse reaction that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect. Severe AE= "Severe" refers to the intensity of an AE; the event itself may be of relatively minor medical significance but intense.

Time frame:
From first dose of study drug until end of the study (up to 48 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsTreatment ATreatment B
Number of patients with TEAEs379380
Number of patients with ADRs3819
Number of patients with serious TEAEs3241
Number of patients with severe TEAEs5679
Number of patients with TEAEs leading to death12
Number of patients with TEAEs leading to withdrawal1021
SecondaryNumber of Patients Who Required > 6 Rescue Inhalations Per Day for at Least Two Consecutive Days During During Treatment Period

Use of reliever medication was derived from the data of SpirotelTM. The event "more than six reliever medications per day for two consecutive days" is defined as at least two consecutive days with more than six puffs of reliever medication in the day.

Time frame:
From first dose of study drug until end of the study (up to 48 weeks)
Reported as:
Count of participants · Participants
Number of Patients Who Required > 6 Rescue Inhalations Per Day for at Least Two Consecutive Days During During Treatment Period
ParticipantsTreatment ATreatment B
Number of Patients Who Required > 6 Rescue Inhalations Per Day for at Least Two Consecutive Days During During Treatment Period5970

Adverse events

Collected over From first dose of study drug to end of the study (Up to 48 Weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A1/854 (0.1%)32/854 (3.7%)370/854 (43.3%)
Treatment B2/854 (0.2%)41/854 (4.8%)360/854 (42.2%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventTreatment ATreatment B
AsthmaRespiratory, thoracic and mediastinal disorders8/85419/854
PneumoniaInfections and infestations3/8542/854
Tendon ruptureInjury, poisoning and procedural complications0/8542/854
Angina pectorisCardiac disorders1/8541/854
Atrial fibrillationCardiac disorders0/8541/854
Cardiopulmonary failureCardiac disorders0/8541/854
Myocardial infarctionCardiac disorders1/8541/854
Duodenal ulcerGastrointestinal disorders1/8540/854
Gastrooesophageal reflux diseaseGastrointestinal disorders1/8540/854
HaemorrhoidsGastrointestinal disorders0/8541/854
Most frequent other events
Showing 10 of 256
Most frequent other events
EventTreatment ATreatment B
AsthmaRespiratory, thoracic and mediastinal disorders103/854158/854
NasopharyngitisInfections and infestations74/85472/854
DyspnoeaRespiratory, thoracic and mediastinal disorders25/85431/854
HeadacheNervous system disorders28/85418/854
BronchitisInfections and infestations26/85419/854
InfluenzaInfections and infestations7/85417/854
RhinitisInvestigations16/8547/854
CoughRespiratory, thoracic and mediastinal disorders16/85413/854
HypertensionVascular disorders16/85414/854
PharyngitisInfections and infestations13/85415/854

Baseline characteristics

Intention-to-treat population (ITT), defined as all randomized patients who took at least one dose of study medication and with at least one available evaluation of efficacy after the baseline.

Age, Continuous
Age, Continuous(Years)Foster (Treatment A)Foster + Ventolin (Treatment B)Total
Mean48.9 ± 14.246.6 ± 13.847.8 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Foster (Treatment A)Foster + Ventolin (Treatment B)Total
Female5215281049
Male331321652
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Foster (Treatment A)Foster + Ventolin (Treatment B)Total
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American011
White8358271662
More than one race011
Unknown or Not Reported161834
Region of Enrollment
Region of Enrollment(participants)Foster (Treatment A)Foster + Ventolin (Treatment B)Total
Bulgaria9694190
Croatia222244
Czechia414182
France262450
Germany353974
Italy464490
Poland256257513
Romania464793
Russia120119239
Serbia454489
Spain101
Turkey303060
Ukraine8887175
United Kingdom011
08

Study locations

206 sites
  • Chiesi Site No 103
    Burgas, Bulgaria
  • Chiesi Site No 107
    Pleven, Bulgaria
  • Chiesi Site No 105
    Plovdiv, Bulgaria
  • Chiesi Site No 111
    Plovdiv, Bulgaria
  • Chiesi Site No 115
    Plovdiv, Bulgaria
  • Chiesi Site No 102
    Rousse, Bulgaria
  • Chiesi Site No 104
    Sofia, Bulgaria
  • Chiesi Site No 108
    Sofia, Bulgaria
  • Chiesi Site No 109
    Sofia, Bulgaria
  • Chiesi Site No 110
    Sofia, Bulgaria
  • Chiesi Site No 113
    Sofia, Bulgaria
  • Chiesi Site No 117
    Sofia, Bulgaria
  • Chiesi Site No 106
    Stara Zagora, Bulgaria
  • Chiesi Site No 116
    Troyan Municipality, Bulgaria
  • Chiesi Site No 0101
    Varna, Bulgaria
  • Chiesi Site No 112
    Veliko Tarnovo, Bulgaria
  • Chiesi Site No 305
    Osijek, Croatia
  • Chiesi Site No 304
    Rijeka, Croatia
  • Chiesi Site No 306
    Zadar, Croatia
  • Chiesi Site No 301
    Zagreb, Croatia
  • Chiesi Site No 302
    Zagreb, Croatia
  • Chiesi Site No 307
    Zagreb, Croatia
  • Chiesi Site No 201
    Beroun, Czechia
  • Chiesi Site No 206
    Brno, Czechia
  • Chiesi Site No 207
    Brno, Czechia
  • Chiesi Site No 202
    Prague, Czechia
  • Chiesi Site No 203
    Prague, Czechia
  • Chiesi Site No 204
    Prague, Czechia
  • Chiesi Site No 205
    Prague, Czechia
  • Chiesi Site No 208
    Prague, Czechia
  • Chiesi Site No 428
    Angoulême, France
  • Chiesi Site No 421
    Castelnau-le-Lez, France
  • Chiesi Site No 434
    Chauny, France
  • Chiesi Site No 403
    Dijon, France
  • Chiesi Site No 408
    Hyères, France
  • Chiesi Site No 424
    Marmande, France
  • Chiesi Site No 410
    Marseille, France
  • Chiesi Site No 436
    Marseille, France
  • Chiesi Site No 418
    Montpellier, France
  • Chiesi Site No 417
    Nice, France
  • Chiesi Site No 435
    Nîmes, France
  • Chiesi Site No 426
    Ollioules, France
  • Chiesi Site No 401
    Paris, France
  • Chiesi Site No 423
    Paris, France
  • Chiesi Site No 404
    Perpignan, France
  • Chiesi Site No 425
    Pézenas, France
  • Chiesi Site No 405
    Poitiers, France
  • Chiesi Site No 416
    Saint-Etienne, France
  • Chiesi Site No 420
    Saint-Girons, France
  • Chiesi Site No 402
    Saint-Michel, France
  • Chiesi Site No 411
    Saint-Quentin, France
  • Chiesi Site No 406
    Soissons, France
  • Chiesi Site No 422
    Toulon, France
  • Chiesi Site No 432
    Toulon, France
  • Chiesi Site No 414
    Verdun, France
  • Chiesi Site No 514
    Bochum, Germany
  • Chiesi Site No 520
    Bonn, Germany
  • Chiesi Site No 510
    Cologne, Germany
  • Chiesi Site No 502
    Dortmund, Germany
  • Chiesi Site No 516
    Duisburg, Germany
  • Chiesi Site No 504
    Düren, Germany
  • Chiesi Site No 503
    Frankfurt, Germany
  • Chiesi Site No 511
    Frankfurt, Germany
  • Chiesi Site No 506
    Hagen, Germany
  • Chiesi Site No 513
    Hamburg, Germany
  • Chiesi Site No 508
    Koblenz, Germany
  • Chiesi Site No 509
    Koblenz, Germany
  • Chiesi Site No 519
    Krefeld, Germany
  • Chiesi Site No 512
    Ludwigshafen, Germany
  • Chiesi Site No 505
    München, Germany
  • Chiesi Site No 515
    Neuss, Germany
  • Chiesi Site No 501
    Weyhe, Germany
  • Chiesi Site No 518
    Witten, Germany
  • Chiesi Site No 606
    Benevento, Italy
  • Chiesi Site No 633
    Brescia, Italy
  • Chiesi Site No 632
    Castrovillari, Italy
  • Chiesi Site No 612
    Cittadella, Italy
  • Chiesi Site No 607
    Crema, Italy
  • Chiesi Site No 601
    Ferrara, Italy
  • Chiesi Site No 610
    Foggia, Italy
  • Chiesi Site No 604
    Genova, Italy
  • Chiesi Site No 605
    Genova, Italy
  • Chiesi Site No 619
    Impruneta, Italy
  • Chiesi Site No 631
    Messina, Italy
  • Chiesi Site No 627
    Milan, Italy
  • Chiesi Site No 636
    Milan, Italy
  • Chiesi Site No 608
    Modena, Italy
  • Chiesi Site No 611
    Montescano, Italy
  • Chiesi Site No 635
    Naples, Italy
  • Chiesi Site No 603
    Palermo, Italy
  • Chiesi Site No 624
    Palermo, Italy
  • Chiesi Site No 630
    Palermo, Italy
  • Chiesi Site No 615
    Parma, Italy
  • Chiesi Site No 628
    Perugia, Italy
  • Chiesi Site No 613
    Pietra Ligure, Italy
  • Chiesi Site No 602
    Pisa, Italy
  • Chiesi Site No 625
    Reggio Calabria, Italy
  • Chiesi Site No 618
    Roma, Italy
  • Chiesi Site No 626
    Roma, Italy
  • Chiesi Site No 609 "Sesto San Giovanni (MI)"
    Sesto San Giovanni, Italy

Showing the first 100 of 206 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, Rabe KF. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med. 2013 Mar;1(1):23-31. doi: 10.1016/S2213-2600(13)70012-2. Epub 2013 Mar 4. PubMed 24321801 ↗
  • Morjaria JB, Rigby AS, Morice AH. Symptoms and exacerbations in asthma: an apparent paradox? Ther Adv Chronic Dis. 2019 Oct 24;10:2040622319884387. doi: 10.1177/2040622319884387. eCollection 2019. PubMed 31695864 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2009 to primary completion in Dec 2010, 20 months.

Results were first posted in May 2026, 15 years 5 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 20 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2009
First posted
Mar 16, 2009
StartActual
Mar 20, 2009
Primary completionActual
Dec 7, 2010
CompletionActual
Dec 7, 2010
Results first posted
May 7, 2026
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00861926
Responsible party
Sponsor
First posted
Mar 16, 2009
Start date
Mar 20, 2009
Primary completion
Dec 7, 2010
Completion
Dec 7, 2010
Results posted
May 7, 2026
Last update
May 7, 2026

Study contacts

Alberto Papi, Professor
principal investigator · Universita degli Studi di Ferrara

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beclomethasone · Formoterol

Start the discussion